Related Experiment Video
Updated: Jun 11, 2026
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
Published on: May 25, 2022
Correcting diastolic dysfunction by Ca2+ desensitizing troponin in a transgenic mouse model of restrictive
Yuejin Li1, Pierre-Yves Jean Charles, Changlong Nan
1Department of Basic Science, College of Biomedical Science, Florida Atlantic University, Boca Raton, FL 33431, USA.
Abstract:
Several cardiac troponin I (cTnI) mutations are associated with restrictive cardiomyopathy (RCM) in humans. We have created transgenic mice (cTnI(193His) mice) that express the corresponding human RCM R192H mutation. Phenotype of this RCM animal model includes restrictive ventricles, biatrial enlargement and sudden cardiac death, which are similar to those observed in RCM patients carrying the same cTnI mutation. In the present study, we modified the overall cTnI in cardiac muscle by crossing cTnI(193His) mice with transgenic mice expressing an N-terminal truncated cTnI (cTnI-ND) that enhances relaxation. Protein analyses determined that wild type cTnI was replaced by cTnI-ND in the heart of double transgenic mice (Double TG), which express only cTnI-ND and cTnI R193H in cardiac myocytes. The presence of cTnI-ND effectively rescued the lethal phenotype of RCM mice by reducing the mortality rate. Cardiac function was significantly improved in Double TG mice when measured by echocardiography. The hypersensitivity to Ca(2+) and the prolonged relaxation of RCM cTnI(193His) cardiac myocytes were completely reversed by the presence of cTnI-ND in RCM hearts. The results demonstrate that myofibril hypersensitivity to Ca(2+) is a key mechanism that causes impaired relaxation in RCM cTnI mutant hearts and Ca(2+) desensitization by cTnI-ND can correct diastolic dysfunction and rescue the RCM phenotypes, suggesting that Ca(2+) desensitization in myofibrils is a therapeutic option for treatment of diastolic dysfunction without interventions directed at the systemic beta-adrenergic-PKA pathways.
Insights
Introducing a novel therapeutic strategy for restrictive cardiomyopathy (RCM), this study demonstrates that calcium desensitization of myofibrils can reverse diastolic dysfunction and rescue RCM phenotypes in a mouse model. This approach offers a potential treatment for RCM without systemic interventions.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Genetic Medicine
Background:
- Mutations in cardiac troponin I (cTnI) are linked to human restrictive cardiomyopathy (RCM).
- A transgenic mouse model (cTnI(193His)) mimicking human RCM exhibits restrictive ventricles, atrial enlargement, and sudden death.
Purpose of the Study:
- To investigate the therapeutic potential of modifying cardiac cTnI in an RCM mouse model.
- To determine if introducing an N-terminal truncated cTnI (cTnI-ND) can rescue the lethal RCM phenotype.
Main Methods:
- Crossed cTnI(193His) mice with transgenic mice expressing cTnI-ND.
- Analyzed cardiac protein expression in double transgenic (Double TG) mice.
- Assessed cardiac function and myocyte relaxation using echocardiography and cellular assays.
Main Results:
- The Double TG mice, expressing both cTnI-ND and cTnI R193H, showed a significantly reduced mortality rate.
- Cardiac function and relaxation were markedly improved in Double TG mice.
- Myofibril hypersensitivity to Ca(2+) and prolonged relaxation in RCM myocytes were reversed by cTnI-ND.
Conclusions:
- Myofibril Ca(2+) hypersensitivity is a key mechanism driving diastolic dysfunction in RCM.
- Ca(2+) desensitization via cTnI-ND effectively corrects diastolic dysfunction and rescues RCM phenotypes.
- Myofibril Ca(2+) desensitization represents a potential therapeutic strategy for RCM and diastolic dysfunction.
